US4621052A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for the production of human epidermal growth factor
Assignee: Hayashibara Seibutsu Kagaku Kenkyujo KK
•
Filing: 1984-06-14
•
Granted: 1986-11-04
•
Expires: 2004-06-14
Abstract
Abstract The present invention relates to a process for the production of human epidermal growth factor (hEGF). More precisely, the present invention relates to a process for the mass production of hEGF, comprising in vivo or in vitro multiplication of human cells capable of producing hEGF, and in vitro cultivation of the multiplied human cells to produce hEGF. The hEGF production according to the present invention is much higher than that attained by conventional processes; thus, hEGF can be obtained in a sufficient amount for use in the prevention and treatment of human diseases.
Inventors
- 👤 Kaname Sugimoto
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 18:01
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/485; C12; C12N; C12N1/00; A; A61; A61K; A61K35/00; A61K35/12; A61K38/00; C12R; C12R2001/00; C12R2001/91; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
41 words
A process for producing human epidermal growth factor (hEGF), comprising: culturing human tumor forming cells capable of producing hEGF on a culture medium under conditions appropriate to accumulate a substantial amount of hEGF; and recovering the accumulated hEGF from the culture.
Claim 2
Dependent Claim
41 words
A process for producing human epidermal growth factor (hEGF), comprising: culturing human tumor forming cells capable of producing hEGF on a culture medium under conditions appropriate to accumulate a substantial amount of hEGF; and recovering the accumulated hEGF from the culture.
Claim 3
Dependent Claim
21 words
A process in accordance with claim 1, wherein said human cells capable of producing hEGF are human submaxillary gland tumor cells.
Claim 4
Dependent Claim
20 words
A process in accordance with claim 1, wherein said human cells capable of producing hEGF are human lung carcinoma cells.
Claim 5
Dependent Claim
20 words
A process in accordance with claim 1, wherein said human cells capable of producing hEGF are human bladder carcinoma cells.
Claim 6
Dependent Claim
44 words
A process for producing human epidermal growth factor (hEGF) comprising: culturing hybridoma cells of hEGF-producing human cells and a human lymphoblastoid line on a culture medium under conditions appropriate to accumulate a substantial amount of hEGF; and recovering the accumulated hEGF from the culture.
Claim 7
Dependent Claim
44 words
A process for producing human epidermal growth factor (hEGF) comprising: culturing hybridoma cells of hEGF-producing human cells and a human lymphoblastoid line on a culture medium under conditions appropriate to accumulate a substantial amount of hEGF; and recovering the accumulated hEGF from the culture.
Claim 8
Dependent Claim
18 words
A process in accordance with claim 5, wherein said hEGF-producing human cells are human submaxillary gland tumor cells.
Claim 9
Dependent Claim
17 words
A process in accordance with claim 5, wherein said hEGF-producing human cells are human lung carcinoma cells.
Claim 10
Dependent Claim
17 words
A process in accordance with claim 5, wherein said hEGF-producing human cells are human bladder carcinoma cells.
Claim 11
Dependent Claim
16 words
A process in accordance with claim 5, wherein said human lymphoblastoid line is of leukemic origin.
Claim 12
Dependent Claim
25 words
A process in accordance with claim 5, wherein said human lymphoblastoid line is a member selected from the group consisting of Namalwa, JBL, and BALL-1.
Claim 13
Dependent Claim
63 words
A process in accordance with claim 5, wherein said hybridoma cells are obtained by: suspending hEGF-producing human cells together with a human lymphoblastoid line in a salt solution containing an effective amount of a cell fusion inducing agent; allowing the resultant cell suspension to stand for a period sufficient to effect cell fusion; and selecting or cloning hybridoma cells capable of producing hEGF.
Claim 14
Dependent Claim
21 words
A process in accordance with claim 11, wherein said cell fusion inducing agent is an activated Sendai virus or polyethylene glycol.
Claim 15
Dependent Claim
71 words
A process in accordance with claim 5, wherein said hybridoma cells used in said culturing step are multiplied hybridoma cells obtained by: implanting said hybridoma cells in an immunodeficient or immunosuppressed non-human warm-blooded animal; feeding the animal to allow said hybridoma cells to utilize the nutrient body fluid of the animal for their multiplication; and extracting and disaggregating the resultant tumor, formed in the animal, to obtain the multiplied hybridoma cells.
Claim 16
Dependent Claim
68 words
A process in accordance with claim 13, wherein said hybridoma cells used in said implanting step are obtained by: suspending hEGF-producing human cells together with a human lymphoblastoid line in a salt solution containing an effective amount of a cell fusion inducing agent; allowing the resultant cell suspension to stand for a period sufficient to effect cell fusion; and selecting or cloning hybridoma cells capable of producing hEGF.
Claim 17
Dependent Claim
18 words
A process in accordance with claim 13, wherein said non-human warm-blooded animal is a fowl or a mammalian.
Claim 18
Dependent Claim
39 words
A process in accordance with claim 13, wherein said non-human warm-blooded animal is a member selected from the group consisting of chicken, pigeon, dog, cat, monkey, goat, pig, cow, horse, guinea pig, rabbit, rat, hamster, nude mouse and mouse.
Claim 19
Dependent Claim
106 words
A process in accordance with claim 5, wherein said hybridoma cells used in said culturing step are multiplied hybridoma cells obtained by: suspending said hybridoma cells in a device in which the nutrient body fluid of a non-human warm-blooded animal can be supplied to said hybridoma cells; embedding or placing said device in or on a non-human warm-blooded animal in a manner such that the nutrient body fluid of said animal is supplied to the hybridoma cells within said device; feeding said animal to allow said hybridoma cells to utilize the nutrient body fluid for their multiplication; and harvesting the multiplied hybridoma cells from the device.
Claim 20
Dependent Claim
68 words
A process in accordance with claim 17, wherein said hybridoma cells used in said suspending step are obtained by: suspending hEGF-producing human cells together with a human lymphoblastoid line in a salt solution containing an effective amount of a cell fusion inducing agent; allowing the resultant cells suspension to stand for a period sufficient to effect cell fusion; and selecting or cloning hybridoma cells capable of producing hEGF.
Claim 21
Dependent Claim
39 words
A process in accordance with claim 17, wherein said device is a diffusion chamber equipped with a membrane filter, ultra filter or hollow fiber having a nominal pore size in the range of 10 -7 to 10 -5 m.
Claim 22
Dependent Claim
18 words
A process in accordance with claim 17, wherein said non-human warm-blooded animal is a fowl or a mammalian.
Claim 23
Dependent Claim
39 words
A process in accordance with claim 17, wherein said non-human warm-blooded animal is a member selected from the group consisting of chicken, pigeon, dog, cat, monkey, goat, pig, cow, horse, guinea pig, rabbit, rat, hamster, nude mouse and mouse.
References Cited (Backward Citations)
US3917824A
Cited
US4135975A
Cited
US4276282A
Cited
US4242460A
Cited
US4285929A
Cited
US4328207A
Cited
US4383036A
Cited
US4377513A
Cited
US4383034A
Cited
US4383035A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-11-03 | 1990-05-05 | 1990-11-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-11-03 | 1994-05-05 | 1994-11-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-11-03 | 1998-05-05 | 1998-11-04 | $7700.00 | Window Closed / Lapsed |